Eversource Energy is updating its Residential Energy Efficiency program for 2026, offering enhanced incentives for heat pumps, weatherization, and smart thermostats to help customers offset high energy costs. The program, part of the broader Mass Save initiative, aims to cover a significant portion of upfront costs for eligible customers through rebates and federal tax credits. It also focuses on whole-home energy assessments and supports state decarbonization goals by encouraging deeper, structural upgrades.

BJ’s Restaurants Inc. has appointed Monika Saxena as its new brand president, effective June 3. Saxena brings over 20 years of marketing experience, including a recent role as executive vice president of brand marketing for LongHorn Steakhouse at Darden Restaurants Inc. CEO Lyle Tick praised her track record of delivering results through strong brand positioning and a focus on product quality and guest experience.

Institutional investors, including several prominent hedge funds and long-term investors, significantly increased their holdings in Netflix Inc (NFLX) according to recent 13F filings. Notable buyers include Jeremy Grantham, Tom Russo, and Cliff Asness, with Steve Cohen and Chris Bloomstran initiating new positions. This accumulation reflects strong confidence in Netflix's continued subscriber growth, expanding advertising revenue, improving operating margins, and robust free cash flow generation.

DexCom Inc. stock (DXCM) decreased by 1.53% to $74.22 on Monday, underperforming a generally positive market session where the S&P 500 and Dow Jones Industrial Average both saw gains. This decline broke a two-day winning streak for DexCom.

HP Inc. (HPQ) experienced a 2.54% drop in its stock price on Monday, closing at $24.60, despite a positive trading session for the broader market. This performance left HP Inc. 17.03% below its 52-week high. The S&P 500 Index and Dow Jones Industrial Average both saw gains, rising 1.65% and 0.92% respectively.

Exxon Mobil has applied for an environmental authorization to conduct a 35-well exploration campaign in Guyana's Stabroek block, approximately 120 miles off the Atlantic coast. The campaign is planned to run from 2028 through 2033. This move was reported by the environmental regulator EPA.

Eversource Energy's Greater Cambridge Energy Project is undertaking significant grid upgrades in Cambridge, Massachusetts, to meet increasing electricity demand from the life sciences sector, universities, and residents. This multi-year initiative involves new underground transmission lines and substation expansions to enhance reliability, support clean energy goals, and accommodate future electrification while minimizing urban disruption. The project is a key part of Eversource's strategy to achieve carbon-neutral operations by 2030 and manage regional growth.

Raymond James has initiated coverage on Aktis Oncology (NASDAQ:AKTS) with a Strong Buy rating and a $40.00 price target, commending its differentiated miniprotein-enabled radioligand therapy platform. The firm anticipates the company's two lead programs, AKY-1189 and AKY-2519, to report initial clinical data next year, projecting significant revenue opportunities exceeding $1 billion, and noted additional upside from expansion, new therapies, and a research deal with Lilly. This positive outlook is further bolstered by Lilly's strong financial health and recent significant developments in its own drug pipeline.

Rivian CEO RJ Scaringe announced that the company plans to release a supervised self-driving system, similar to Tesla's Full Self-Driving, later this year for its second-generation vehicles and the new R2. This new advanced driver-assistance system (ADAS) will allow for point-to-point driving with supervision. Scaringe also noted that unsupervised, hands-free, eye-off driving capabilities are projected to be released by 2027, aligning with Rivian's broader strategy to develop autonomous driving for future robotaxi fleets.

Amgen Inc. has hired Michael Lamoureux of Capitol Counsel for lobbying on medical and disease research issues, amid increasing congressional scrutiny over drug pricing and tax practices. This move adds an external voice to Amgen's advocacy efforts as the pharmaceutical industry faces pressure from lawmakers regarding pricing transparency and NIH funding cuts. Amgen is also publicly supporting the Prescription Information Modernization Act, a bill aimed at allowing electronic prescribing information for drugs.